Why the study?
Does enoxaparin reduce permanent ischemic lesions in patients with aneurysmal subarachnoid hemorrhage?
Population
170 patients with aneurysmal subarachnoid hemorrhage who underwent surgery for a ruptured aneurysm, mean age…
Comparison
Enoxaparin 40 mg subcutaneously once daily… vs Placebo.
Design
RCT, randomized in a prospective, double-blind, placebo-controlled trial…
Follow-up
3 months
Authors
Loading...
Enoxaparin should not be used to prevent ischemic lesions after SAH; challenges its prophylactic role and redirects research to hemorrhage burden and delayed ischemia.
Does enoxaparin reduce permanent ischemic lesions in patients with aneurysmal subarachnoid hemorrhage?
Enoxaparin does not reduce the risk of permanent ischemic lesions after aneurysmal subarachnoid hemorrhage, which are instead predicted by bleeding severity, delayed ischemia, and surgical factors.
Juvela et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: